Stock EXEL EXELIXIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
23.7 USD +0.72% Intraday chart for Exelixis, Inc. +5.24% -1.21%
Apr. 12 North American Morning Briefing : Big Banks Kick -2- DJ
Apr. 11 Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25 MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 5,354 6,227 5,784 5,174 7,460 6,987 - -
Enterprise Value (EV) 1 4,502 5,020 4,317 3,865 6,465 5,876 5,335 4,666
P/E ratio 17.3 x 57.3 x 25.4 x 28.6 x 36.9 x 19.2 x 16 x 11.8 x
Yield - - - - - - - -
Capitalization / Revenue 5.53 x 6.31 x 4.03 x 3.21 x 4.08 x 3.66 x 3.36 x 3.01 x
EV / Revenue 4.65 x 5.08 x 3.01 x 2.4 x 3.53 x 3.08 x 2.57 x 2.01 x
EV / EBITDA 11.9 x 42.1 x 14.4 x 17.4 x 32.9 x 12.3 x 9.4 x 6.61 x
EV / FCF 8.76 x 28.1 x 12.8 x 17.2 x 22.1 x 15.8 x 11.1 x 8.47 x
FCF Yield 11.4% 3.56% 7.8% 5.8% 4.53% 6.35% 8.99% 11.8%
Price to Book 3.19 x 3.4 x 2.64 x 2.09 x 3.21 x 2.81 x 2.24 x 1.83 x
Nbr of stocks (in thousands) 303,846 310,244 316,397 322,561 310,974 294,800 - -
Reference price 2 17.62 20.07 18.28 16.04 23.99 23.70 23.70 23.70
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 967.8 987.5 1,435 1,611 1,830 1,911 2,078 2,323
EBITDA 1 377.8 119.2 300.3 222.4 196.6 478.3 567.4 705.9
EBIT 1 369.5 110.1 286.7 201.5 170.9 406.1 490.5 669.9
Operating Margin 38.18% 11.14% 19.98% 12.51% 9.34% 21.25% 23.61% 28.84%
Earnings before Tax (EBT) 1 398.1 130.8 294.2 234.4 257.5 483.2 572.9 749.3
Net income 1 321 111.8 231.1 182.3 207.8 375.5 445.6 598.7
Net margin 33.17% 11.32% 16.1% 11.31% 11.35% 19.65% 21.44% 25.77%
EPS 2 1.020 0.3500 0.7200 0.5600 0.6500 1.236 1.477 2.005
Free Cash Flow 1 514.1 178.6 336.6 224.2 292.9 373 479.8 551
FCF margin 53.12% 18.09% 23.46% 13.91% 16% 19.52% 23.09% 23.72%
FCF Conversion (EBITDA) 136.08% 149.86% 112.08% 100.81% 148.96% 77.98% 84.56% 78.06%
FCF Conversion (Net income) 160.16% 159.81% 145.67% 122.97% 140.95% 99.34% 107.67% 92.04%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 328.4 451.1 356 419.4 411.7 423.9 408.8 469.8 471.9 479.7 460.5 481.3 488 477.6 459.1
EBITDA 1 - - - - 88.28 -42.13 - - - 88.31 135.6 131.8 31.71 120.1 -
EBIT 1 51.62 116.6 83.24 83.71 82.61 -48.08 28.83 77.85 -17.58 81.79 79.99 101.9 93.64 136.3 96.46
Operating Margin 15.72% 25.86% 23.38% 19.96% 20.06% -11.34% 7.05% 16.57% -3.73% 17.05% 17.37% 21.18% 19.19% 28.53% 21.01%
Earnings before Tax (EBT) 1 53.26 118 85.23 88.51 92.04 -31.43 48.28 100.4 5.818 103 101.1 125.6 110.3 141 113.7
Net income 1 38.2 95.17 68.57 70.67 73.21 -30.17 40.03 81.18 1.041 85.52 80.42 97.32 89.52 105.7 89.8
Net margin 11.63% 21.09% 19.26% 16.85% 17.78% -7.12% 9.79% 17.28% 0.22% 17.83% 17.46% 20.22% 18.35% 22.14% 19.56%
EPS 2 0.1200 0.2900 0.2100 0.2200 0.2300 -0.0900 0.1200 0.2500 - 0.2700 0.2377 0.3099 0.2996 0.3891 0.3450
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/2/21 2/17/22 5/10/22 8/9/22 11/1/22 2/7/23 5/9/23 8/1/23 11/1/23 2/6/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 852 1,207 1,467 1,308 995 1,111 1,652 2,321
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 514 179 337 224 293 373 480 551
ROE (net income / shareholders' equity) 21.6% 10.8% 11.3% 7.76% 8.74% 15.5% 16.4% 16.8%
ROA (Net income/ Total Assets) 19.4% - 9.72% 6.41% 6.91% 11.2% 11% 12.6%
Assets 1 1,654 - 2,377 2,844 3,007 3,352 4,051 4,752
Book Value Per Share 2 5.530 5.910 6.930 7.680 7.480 8.420 10.60 12.90
Cash Flow per Share 2 1.670 0.6600 1.240 1.120 1.040 1.330 1.730 2.300
Capex 1 12.8 30.3 64.2 138 40.5 35.2 33.7 34.9
Capex / Sales 1.33% 3.07% 4.48% 8.59% 2.21% 1.84% 1.62% 1.5%
Announcement Date 2/25/20 2/10/21 2/17/22 2/7/23 2/6/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Exelixis, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
23.7 USD
Average target price
26.63 USD
Spread / Average Target
+12.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
EXELIXIS, INC. Stock Exelixis, Inc.
-1.21% 6.99B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Financials Exelixis, Inc.